1. Home
  2. ZS vs BIIB Comparison

ZS vs BIIB Comparison

Compare ZS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

HOLD

Current Price

$152.62

Market Cap

24.7B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.32

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZS
BIIB
Founded
2007
1978
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.7B
27.1B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
ZS
BIIB
Price
$152.62
$183.32
Analyst Decision
Buy
Buy
Analyst Count
38
27
Target Price
$268.57
$194.72
AVG Volume (30 Days)
3.1M
827.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
30.77
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$27.60
N/A
Revenue Next Year
$19.67
N/A
P/E Ratio
N/A
$21.03
Revenue Growth
N/A
2.22
52 Week Low
$140.56
$110.04
52 Week High
$336.99
$202.41

Technical Indicators

Market Signals
Indicator
ZS
BIIB
Relative Strength Index (RSI) 40.03 46.95
Support Level $140.56 $181.24
Resistance Level $166.10 $186.17
Average True Range (ATR) 7.52 5.30
MACD 1.68 -1.14
Stochastic Oscillator 48.52 16.93

Price Performance

Historical Comparison
ZS
BIIB

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: